广东横琴新创益

Guangdong Hengqin Xinchuangyi Pharmaceutical Technology is a clinical-stage biotechnology company based in Zhuhai, China, focused on the discovery and development of innovative small molecule therapeutics. The company primarily targets metabolic diseases such as non-alcoholic steatohepatitis (NASH), obesity, and type 2 diabetes, as well as various oncology indications. Its lead candidate, XCY-2002, is a dual agonist of the GLP-1 and glucagon receptors, designed to provide superior efficacy in weight loss and liver fat reduction. Xinchuangyi leverages a proprietary structure-based drug design platform to optimize the potency and selectivity of its pipeline assets. The company aims to address significant unmet medical needs through its portfolio of high-potential drug candidates.